"We look forward to working with lawmakers to hold Secretary Kennedy to his promise to maintain our nation's vaccine approval ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

Sonya Stokes, an emergency room physician in the San Francisco Bay Area, braces herself for a daily deluge of patients sick ...

The rate of Americans visiting doctors’ offices for flu-like illness is continuing to reach record levels, new CDC data ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) ...

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

The CDC’s incoming head, former Congressman Dave Weldon, a physician, has been commissioned by Trump to “ focus on the ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

which may portend similar efficacy during the upcoming Northern Hemisphere flu season if similar A(H3N2) viruses predominate, Centers for Disease Control and Prevention (CDC) researchers report.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...